FLORENCE (ITALPRESS) – The Menarini Group, an internationally leading company in the pharmaceutical and diagnostic sectors, and Stemline Therapeutics, a fully owned subsidiary of the Menarini Group focused on introducing innovative treatments for cancer patients, announced today a strategic partnership with Clinica Group, a leading company in Algeria’s pharmaceutical services sector. The goal is to make Menarini Group’s innovative oncology drugs available to Algerian patients.
“This partnership highlights the commitment of both companies to improving access to life-changing therapies for people with cancer in Algeria,” a statement reads. The partnership will leverage Clinica Group’s established presence in the region and its deep knowledge of the Algerian healthcare system, facilitating access to Menarini Group’s oncology portfolio in the country. This initiative represents an important step forward in addressing the still unmet medical needs of cancer patients in Algeria by offering them advanced therapeutic options that were previously unavailable.
The collaboration is also part of a broader national cancer control plan promoted by Algerian authorities, aimed at improving disease management and clinical outcomes.
“We are pleased to launch this collaboration with Clinica Group, a company that shares our commitment to patient care and has a proven track record of success in Algeria,” said Elcin Barker Ergun, CEO of the Menarini Group.
“The collaboration is a tangible demonstration of Menarini’s ongoing commitment to expanding access to our cutting-edge oncology therapies worldwide. We believe that by combining Menarini Group’s scientific innovations with Clinica Group’s strong local presence, we can truly make a difference for Algerian cancer patients and their families.”
“The partnership with the Menarini Group marks a turning point for cancer care in Algeria. We are proud to join forces with a global oncology leader, which will enable us to offer our patients the treatments they need,” said Salah Sahraoui, CEO of Clinica Group. “This collaboration aligns perfectly with Clinica Group’s mission to improve outcomes and further strengthen our leadership position in the Algerian healthcare sector.”
Cancer incidence is on the rise globally, and Algeria is no exception. In Algeria, breast cancer accounts for about 39% of all female cancers, with over 14,000 new cases annually, 60% of which are diagnosed at an advanced stage. Additionally, the incidence and prevalence of multiple myeloma have doubled since 1990, with around 770 new cases diagnosed each year in Algeria, most of them at stage three.
The aim of this partnership is to help mitigate the impact of cancer by providing Algerian patients with timely access to innovative and effective treatment options. Both companies are committed to working closely with healthcare professionals and Algerian regulatory authorities to ensure the safe and effective supply of these medicines.
-Photo Menarini-
(ITALPRESS).
